Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The main objective of this pilot study is to investigate the protein / peptide plasma
profiles before and after treatment with a direct anti-Xa (activated Factor 10) in patients
with non-valvular atrial fibrillation to better understand the mechanisms of action of these
molecules and perform exploratory analyses concerning proteins whose concentrations change
after starting treatment.